These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 32086346)

  • 1. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
    Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
    Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
    Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
    Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
    Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
    J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a
    Sautois B; Loehr A; Watkins SP; Schroeder H; Abida W
    Curr Oncol; 2022 Jun; 29(6):4178-4184. PubMed ID: 35735442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
    Loehr A; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Hussain A; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Dowson M; Golsorkhi T; Chowdhury S; Abida W
    Clin Cancer Res; 2021 Dec; 27(24):6677-6686. PubMed ID: 34598946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    Loehr A; Hussain A; Patnaik A; Bryce AH; Castellano D; Font A; Shapiro J; Zhang J; Sautois B; Vogelzang NJ; Chatta G; Courtney K; Harzstark A; Ricci F; Despain D; Watkins S; King C; Nguyen M; Simmons AD; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):200-209. PubMed ID: 36243543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
    Orme JJ; Taza F; De Sarkar N; Tewari AK; Arsalan Naqvi S; Riaz IB; Childs DS; Omar N; Adra N; Ashkar R; Cheng HH; Schweizer MT; Sokolova AO; Agarwal N; Barata P; Sartor O; Bastos D; Smaletz O; Berchuck JE; McClure H; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Mehra N; Nelson PS; Hwang J; Dehm SM; Shi Q; Fleischmann Z; Sokol ES; Elliott A; Huang H; Bryce A; Marshall CH; Antonarakis ES
    Eur Urol Oncol; 2024 Aug; 7(4):877-887. PubMed ID: 38072760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.
    Sokolova AO; Yu EY; Cheng HH
    Clin Cancer Res; 2020 Jun; 26(11):2439-2440. PubMed ID: 32234758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    Aldea M; Lam L; Orillard E; Llacer Perez C; Saint-Ghislain M; Gravis G; Fléchon A; Roubaud G; Barthelemy P; Ricci F; Priou F; Neviere Z; Beaufils M; Laguerre B; Hardy AC; Helissey C; Ratta R; Borchiellini D; Pobel C; Joly F; Castro E; Thiery-Vuillemin A; Baciarello G; Fizazi K
    Eur J Cancer; 2021 Dec; 159():87-97. PubMed ID: 34742160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Coquan E; Penel N; Lequesne J; Leman R; Lavaud P; Neviere Z; Brachet PE; Meriaux E; Carnot A; Boutrois J; Castera M; Goardon N; Muller E; Leconte A; Thiery-Vuillemin A; Clarisse B; Joly F
    Ther Adv Urol; 2024; 16():17562872241229876. PubMed ID: 38425504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    Fizazi K; Piulats JM; Reaume MN; Ostler P; McDermott R; Gingerich JR; Pintus E; Sridhar SS; Bambury RM; Emmenegger U; Lindberg H; Morris D; Nolè F; Staffurth J; Redfern C; Sáez MI; Abida W; Daugaard G; Heidenreich A; Krieger L; Sautois B; Loehr A; Despain D; Heyes CA; Watkins SP; Chowdhury S; Ryan CJ; Bryce AH;
    N Engl J Med; 2023 Feb; 388(8):719-732. PubMed ID: 36795891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
    Mota JM; Barnett E; Nauseef JT; Nguyen B; Stopsack KH; Wibmer A; Flynn JR; Heller G; Danila DC; Rathkopf D; Slovin S; Kantoff PW; Scher HI; Morris MJ; Schultz N; Solit DB; Abida W
    JCO Precis Oncol; 2020; 4():355-366. PubMed ID: 32856010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    Petrylak DP; Watkins SP; Loehr A
    Front Oncol; 2022; 12():951348. PubMed ID: 35978838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.